Getting a most cancers remedy accepted is a serious milestone. Getting it into the arms of the physicians and sufferers who want it’s a completely different problem altogether. On this episode of the Healthcare Success Podcast, I communicate with Leonard Mazur, Chairman and CEO of Citius Prescribed drugs, about what occurs when a biotech firm strikes from elevating capital to creating income.
Leonard has spent greater than 50 years in prescribed drugs, constructing companies, shopping for and repositioning drug belongings, and studying to take calculated dangers. His entrepreneurial profession gives the backdrop for Citius’s work with LYMPHIR, a remedy for cutaneous T-cell lymphoma (CTCL), a uncommon most cancers. We talk about how the corporate acquired the asset, navigated the regulatory course of, and ready for commercialization.
One essential distinction Leonard makes is that FDA approval isn’t the end line. After the drug acquired approval in 2024, troublesome capital-market situations delayed a full industrial rollout. Citius used that point to organize its distribution, reimbursement, patient-support and field-sales infrastructure, then launched in levels in 2026. The corporate additionally shifted from a predominantly technical group to 1 that wanted skilled industrial management and a coordinated gross sales operation.
For healthcare entrepreneurs, the rare-disease technique is especially instructive. Slightly than reaching a broad inhabitants, Citius makes use of claims information to establish physicians treating CTCL sufferers and perceive their affiliations with educational and neighborhood facilities. Leonard additionally explains the significance of affected person advocacy organizations, key opinion leaders, medical science liaisons and neighborhood remedy entry. Every factor serves a special function, however they should work collectively.
We additionally talk about the potential for future analysis past the drug’s accepted indication, together with investigator-led research together with different most cancers therapies. Leonard is cautious to differentiate promising early findings from what additional scientific information nonetheless wants to determine.
All through the dialog, Leonard returns to a lesson that applies far past prescribed drugs: relationships matter. Skilled companions may help a small firm execute complicated work, whereas longstanding connections with colleagues, physicians and advisers can shorten the training curve. His story is a helpful reminder {that a} profitable launch requires greater than a promising product. It requires capital, operational self-discipline, the precise crew and the flexibility to make these items work collectively.
Observe: The next AI-generated transcript is supplied as an extra useful resource for individuals who want to not hearken to the podcast recording. It has been flippantly edited and reviewed for readability and accuracy.
Stewart Gandolf (Healthcare Success):. Whats up and welcome to the Healthcare Success Podcast. Right this moment I am interviewing Leonard Maser, who’s CEO and Chairman of Sidious Prescribed drugs. To begin with, welcome, Leonard. Thanks.
Leonard Mazur (Citius Prescribed drugs): So thanks. It is a pleasure to be right here and I look and I thanks for the chance to have the ability to take part on this podcast. Thanks once more.
Stewart Gandolf (Healthcare Success): Nice. I am yeah, I am wanting ahead to moving into it. And there is a lot. whenever you your crew reached out to us, there’s a whole lot of issues right here I believed could be related for my viewers and a few new issues to speak about and a few thrilling, enjoyable issues to speak about as nicely within the pharmaceutical world. So, initially, one of many questions that I needed to start out with is give our viewers a little bit little bit of context. You spent over 50 years in prescribed drugs, and now you’ve got invested, personally invested over 20 million {dollars} in Citius. Earlier than we get into the drug launch itself, you understand, it is like I’ve we’re gonna speak about all that in a minute, however such as you we talked about this offline, lengthy story, however I wanna hear it. Like, how did you find yourself with twenty two million {dollars} to take a position into your personal biotech firm?
Leonard Mazur (Citius Prescribed drugs): What how did I what?
Stewart Gandolf (Healthcare Success): How did you provide you with the cash to spend money on your personal biotech firm? It sounds such as you’ve had a fairly attention-grabbing profession. So I would love a I would love a background.
Leonard Mazur (Citius Prescribed drugs): Properly, what it’s, it is previous to that, I had a accomplice and we might purchase and promote pharmaceuticals, branded ones, often off patent. Then we might repurpose them after which we would promote them off once more. we did that a number of instances they usually had been considered one of them was extraordinarily profitable. We had a serious league. We had a grand slam, not even a house run, so that is what that is what enabled me to do to do that.
Stewart Gandolf (Healthcare Success): That should have been a enjoyable profession. How’d you choose that? how did you choose how did you get inquisitive about that? I am simply curious. We’ll discuss concerning the different stuff in a second. I am simply I at all times love entrepreneurial tales.
Leonard Mazur (Citius Prescribed drugs): Properly, you understand what it was. so I’ve my profession was fairly conventional. moved up the ladder, and I’d been with a number of corporations. They had been all run by entrepreneurs. The very first firm I used to be with in all probability was an organization I actually, actually I actually I beloved it to inform you the reality. It was run by an entrepreneur by the identify of Parker G. Montgomery and referred to as Cooper Labs. It was they made 150 acquisitions.
Stewart Gandolf (Healthcare Success): Wow.
Leonard Mazur (Citius Prescribed drugs): You possibly can think about what that setting was like. So principally and I at all times had what I name the entrepreneurial itch within me. I needed to scratch that. So
Stewart Gandolf (Healthcare Success): Yeah.
Leonard Mazur (Citius Prescribed drugs): on the ripe outdated age of fifty, I lastly determined to go by myself. And I shaped a dermatological product firm. I imply I had no cash, I had nothing, okay? So I it is I constructed that firm on a foundation of relationships that I had with others. So
Stewart Gandolf (Healthcare Success): Yeah.
Leonard Mazur (Citius Prescribed drugs): in the end I put that firm collectively and had income, owned a small manufacturing facility and outdoors of Detroit, Michigan, and in the end offered the corporate to Pierre Fab of France, considered one of France’s largest corporations, as you in all probability know on a worldwide foundation. After which I used to be their US CEO for a few years, then determined I did not need to be working for the French anymore. So I went off by myself once more. And that is once I received into the entire thing about shopping for and promoting medicine. I had a accomplice. We had been we had been whole opposites. It was form of attention-grabbing. And that is what actually made it work. So after which sadly he handed away. And so in the end I offered all the pieces.
What occurred was I received along with Myron Halubia, who had been the president of Roche Laboratories US. I knew Myron for many years, and I mentioned, “Let’s get collectively and type an organization. We’ll see what we are able to in license.” We managed to in license a drug from MD Anderson referred to as Minaloc, which was an antibiotic lock answer for sterilizing contaminated catheters. After which we funded all the pieces ourselves and we went alongside for a few years after which determined we needed to take the corporate public. So we did a reverse merger with one other public firm that allowed us to get a Nasdaq itemizing and we’re off to the races and I you understand, I would be remiss if I did not inform you that deal making is in my blood or my DNA. So anyone got here to me and a banker got here to us, a boutique financial institution, and mentioned, “Hey, I am representing Dr. Reddy’s they usually’re divesting a few of their belongings ‘trigger they have been on a they have been buying branded belongings for a generic firm.” Then sooner or later they awakened and mentioned, You already know what? We’re not a branded firm. We’re strictly a generic firm. And in order that was a chance for us. This drug lymphear, that they had a license on it with E Facet Prescribed drugs. They usually had one affected person left on a scientific trial for cutaneous T cell lymphoma. By coincidence, fully by coincidence, a yr earlier than we even did that transaction, we employed a chief medical officer who was a world-renowned knowledgeable in lymphomas. He spent 23 years at Roswell Park in Buffalo because the an oncologist accountable for lymphoma and myeloma. He revealed 180 papers, if you happen to can think about that. And
Stewart Gandolf (Healthcare Success): Wow.
Leonard Mazur (Citius Prescribed drugs): we introduced him on board. That drug, he knew that drug chilly, all proper, knew all the pieces concerning the class. It was it was a terrific match. It labored out. We put 40 million {dollars} down on the desk at that time and bought that drug. After which that they had one affected person left, that was in September of 2021 by August of 2024. We had been we received an approval. So we have been th that is just about how issues began rolling alongside for us.
Stewart Gandolf (Healthcare Success): I adore it. I simply gotta inform you, I like that entrepreneurial spirit. It is this the form of factor that so we’ll simply have it and it is it is scary and thrilling and invigorating and chances are you’ll wanna do it, however it’s a must to be good at it too. That is the factor.
Leonard Mazur (Citius Prescribed drugs): Properly, you understand what? I occur to stay by sure mottos, okay? One is: failure will not be an possibility. See that I received that from I spent I used to be in a Marine Corps reserve, so I received that in Paris Island at one level. So and the opposite one is: if you happen to’re not residing on the sting, you then’re taking over an excessive amount of area. So okay.
Stewart Gandolf (Healthcare Success): I adore it. I adore it. We received some classes in entrepreneurship right here too. And like on a smaller scale, proudly owning my very own company, beginning it with a accomplice in the beginning from scratch has at all times been, I simply knew I used to be gonna try this. However you are doing it on a lot larger scale. However it’s been enjoyable trip. And I feel it is both you both get it or you do not. And I at all times took threat. And to this present day I nonetheless take dangers. You simply kinda I do not know. It is simply I get used to it. However making an attempt to make them sensible threat, Leonard, not silly threat, sensible threat.
Leonard Mazur (Citius Prescribed drugs): Right. Properly, you understand, once more, what again in my days at Cooper Labs, I realized all about threat taking from the best way the corporate ran and what they did. And I imply, I need you to consider this. This firm principally I helped create Cooper Imaginative and prescient, which we took from 10 million to 600, 700 million, turned considered one of one of many world’s largest eye care corporations. What the what that firm did although, what was actually outstanding, they decided strategically To construct companies round medical specialties. In order that they shaped a dental unit. And that dental unit went out and purchased a tiny little toothbrush firm doing lower than one million {dollars} in income referred to as Oral B.
Grew to become the world’s largest promoting toothbrush. I did not have something to do with that. I gotta be sure everyone understands that. So however I watched that occur. After which what I noticed was that and it was a terrific instance of the form of threat taking the corporate did. After they had been within the ophthalmic enterprise, that they had a chance for a it was an prolonged put on contact lens referred to as Permalens, the primary one. They usually needed to decide about whether or not or to not do scientific trials after which apply for the FDA for an approval. Each guide that got here into the corporate suggested towards it, mentioned the FDA would by no means approve an prolonged put on lens. However there was one PhD that the that the CEO had as his advisor and that one recommended him and mentioned to him, “Go for it. It’s going to clear.” And he was proper. And the CEO was not a technical man in any respect. He was a lawyer by coaching, finance, you understand, that was his space. However it was form of attention-grabbing that he took that threat, a technical threat, that in all probability individuals would you understand, you’re you out of your thoughts or what? You already know?
Stewart Gandolf (Healthcare Success): It is humorous. That is such a that is a terrific story. It is humorous. I keep in mind I hope I am quoting this proper. This has been a very long time in the past, however I heard a narrative speaking about Warren Buffett taking threat. And Warren’s model is a worth man. He would know when he purchased an organization that simply had sell-offable belongings that you possibly can no less than just about break even. However what this what you guys are speaking about is a complete completely different world.
So let’s that was nice. I am actually glad we most individuals in all probability do not ask you about that stuff, however I simply should know that. And I need to know like how you bought right here. So, you understand what the aim of the interview that began although is you are transferring from the elevating capital to creating capital section. And so what occurs when in a website of an organization now that you are going previous all of the work, you’ve got received approvals, issues are starting to occur. Inform me concerning the adjustments which might be happening.
Leonard Mazur (Citius Prescribed drugs): Yeah. So i it’s a change as a result of as you mentioned, you are going from elevating capital to creating capital. Yeah, not that you will cease elevating capital, however you may will not do it on the similar depth, and depth that you just did earlier than. So you’ve got gotta have an organization now, so we had been we had largely technical individuals in an organization for the longest time. So that you had a regulatory, you had anyone with nice experience in CMC, you understand, medical scientific and medical, so all that was a part of the corporate. That was within the firm’s DNA.
After which now swiftly now comes a chance to create income. You gotta usher in a advertising group, you gotta usher in anyone that is received a whole lot of experience in directing and launching, which is admittedly, actually essential. That experience particularly. So we had been lucky that we picked up anyone, his identify is Mike McGuire. He spent 25 years at Hop and La Roche accountable for in the end advertising, launched all their main antibiotics, knew the hospital market chilly, and he was a terrific add-on to addition to our employees as a result of it received us transferring in that course.
So we labored extensively additionally with Eversana. which is a supplier of every kind of providers, largely to smaller biotech pharma corporations. And I’ve had a whole lot of expertise prior to now with startups and getting going. And I do know one factor, I do not desire a warehouse ever reporting to me. So that you rent a 3 PL and principally that they handle delivery, billing, invoicing, all that was in place. Reimbursement received in place. So you’ve got received all these targets that you have to meet and have the corporate actually poised to start out producing the income. And with that working once more with Eversana, we use them to rent the salespeople that we introduced on board and you’re taking off.
So we’re we’re on the level now the place we had for example 25, 24 individuals in an organization. We simply added 29 within the gross sales pressure, so we have doubled our dimension. And it is it is it is it is completely different. The setting turns into completely different as a result of now you are focusing in on income. And now you are wanting, you understand, and I’ve I’ve by the best way, I have been at all times increasingly co extra comfy with income than anything. So the expertise I had right here, I went by means of all these years all these years of no income and simply elevating capital. And I gotta say it was it was such a wierd expertise for me as a result of I used to be so accustomed to having income on a regular basis. And ‘trigger income can cowl in our business, income can cowl a whole lot of sins in case you have excessive gross revenue margins. So you understand, so with that it was it w it was it was totally completely different. It was simply a wholly completely different environment, tradition, all the pieces about it was fully completely different. So
Stewart Gandolf (Healthcare Success): I consider it. It is it is enjoyable.
Leonard Mazur (Citius Prescribed drugs): I you understand, I needed to get used to it, so
Stewart Gandolf (Healthcare Success): I hada good friend of mine who used to personal a drywall firm, had a bunch of individuals working for him. When he lastly retired, he mentioned, It is simply so bizarre to not have individuals on the market getting cash for me. It is it is like, wow, it should have been a enjoyable firm, however was that straightforward it sounds too straightforward.
So I need to take a step again. You talked about Lymphear a second in the past and about and the way you understand, you the story a little bit bit about like how you’ve got found it. It was, I feel, accepted again in 2024, commercially launched in 25 on the finish, very finish of 2025. individuals outdoors the business might assume as soon as you bought FDA approval, it is the end line. However after all, as you are alluding to, you understand, that is only the start. So, what truly has to occur? I imply, you’ve got already talked about a few of the belongings you’ve finished, however what different issues should occur to get an accepted remedy in place? Like, what are a few of the essential…
Leonard Mazur (Citius Prescribed drugs): So it is like this. We truly didn’t launch till 2026 as a result of what occurred was that s the capital markets took a nosedive after we get we get accepted. And I did not I actually did not have enough capital to launch. So we did different issues to prep, get all the pieces prepared, however I needed to wait till these markets actually began to recuperate. After which I received we managed to boost the capital. So we launched in 2026 and we did it in two levels. so all 29 individuals are on board as of this simply this previous September. So it was nearly two years from the time it received accepted earlier than we truly received to {the marketplace}. We launched we truly shipped the drug to wholesalers and all the pieces again to start with of 2026 and received the pipeline all prepared in order that the as soon as the gross sales pressure was absolutely in place. they’d be capable of go in there they usually did not have to fret about something besides promote the drug to the oncologist or the hematologist.
So we had a we had a it is form of a special expertise due to that. So however we’re there and we have I feel we have now a terrific drug. It is received a terrific future forward of it. It is for a really uncommon most cancers referred to as cutaneous T lymphoma. It solely has the which solely has 3,000 sufferers within the within the US. So it is a a lot smaller market section, a lot smaller audience. And the specialty aspect is one thing I am very accustomed to. I’ve at all times been interested in smaller specialties the place you do not want a military. You possibly can go in and you’ll construct a enterprise with a smaller variety of individuals. It’s not like main care the place you gotta have 1,000 individuals no less than on the market within the market. I or I am I am not a believer in that. So I attempt to avoid these sorts of conditions if in any respect attainable.
Stewart Gandolf (Healthcare Success): So we talked offline, it has been some time. Was Lympheer was this initially the concentrating on or was this a type of joyful circumstances the place Lymphia was developed for one thing else after which it turned out this was the precise most cancers for it to
Leonard Mazur (Citius Prescribed drugs): So what occurred was Lymphir had its personal historical past. It had been in the marketplace, ESI had it in the marketplace after which they principally that they had a producing requirement. They needed to modify the drug. They did not should take it off the market. The issue was it was a tough drug to make. They’d inadequate stock to do what the FDA had requested them to do, in order that they determined to tug it off the market whereas they accomplished the extra assessments that the FDA needed or and changes. After which once they went again into the FDA with all the pieces, the FDA mentioned to them, “Sorry, however now you have got you have got a brand new drug. You gotta run one other scientific trial.”
So and so ESI continued with that they usually’ve in a course of they outlicensed it to Dr. Reddy’s however they did all of the work. They did all the pieces. So this drug has gone by means of it is received it is received historical past to it. However the but it surely’s a great drug. It is received good outcomes for it. And it is also received extra legs for the longer term when it comes to potential different makes use of. So an investigator on the College of Pittsburgh determined to check this drug with an investigator IND To check this drug mixed with Keytruda. And what he did is now we’re indicated in blood cancers. He selected to check this in stable tumors in feminine cancers solely, primarily endometrial and ovarian, very exhausting cancers to deal with. And what and the rationale he did is as a result of Lymphir has a really distinctive mechanism of motion. It lowers one thing often called T Rex. within the microenvironment of a most cancers cell. And whereas keytruda will increase T regs. And what you actually need to do briefly is it brings these T Rex down considerably. In order that’s why this investigator selected to take a look at that mixture.
And what he discovered is it is attention-grabbing, he received constructive information, I am going to offer you an instance, 33% goal response charge in endometrial the place usually It may very well be in a single digits. These two cancers are actually powerful. They’re brutal. They’re exhausting to deal with. And I feel there’s there’s some actually stable potential there. we even have one other investigator I and D underway on the College of Minnesota the place it is being checked out mixed with CAR T, which is one other type of breakthrough most cancers remedy. So I feel we received one thing right here that additional scientific information will show it out. So we’re on that. And there is that drug it is form of attention-grabbing that it is kinda it is growing this manner. It is not one thing that we anticipated on the time that once we acquired the drug. We thought we had been gonna be strictly doing CTCL and that was the market alternative for us. However now as soon as all that began coming into play, that actually opened up the world for us.
Stewart Gandolf (Healthcare Success): Yeah, it is wonderful upside. It is humorous, you understand, going again to our earlier dialog, speaking about threat, after which, you understand, going by means of and discovering out, whoops, you want one other scientific trial when the previous firm owned the drug. Like that is not a great threat. After which swiftly, “wait, we have now upside right here, large upside.” Like that is insane.
And it is humorous too, as a result of on this case, that is an space that on the pharma aspect, I am not as near, and I can see how entrepreneurs such as you might be the glue that brings some a drug like this to life, proper? It is not everyone that does this particular form of drug and it is simply it sounds prefer it discovered s sq. into your candy spot.
You already know, uncommon illness medicine. We have had some visitors on our podcast earlier than speaking about uncommon illness and the way that goes whenever you solely have a number of thousand sufferers as a audience to assist, however past the truth that you want lots much less salespeople, what different issues are distinctive to the uncommon illness market as you guys eager about increasing? for instance, are you focusing all of your energies on educational medical facilities? Are you concerned with shopper advocacy teams? Like what are a few of the issues which might be actually essential to you?
Leonard Mazur (Citius Prescribed drugs): Sure, in order that it is attention-grabbing that you just talked about that, the patron advocacy teams as a result of on this specific most cancers, there’s a shopper group of sufferers which have CTCL. They’re lively, they’ve their very own publication, they maintain annual conferences. And we have reached out and we’re involved with them, working together with them, offering them with the inf data on our drug. So it is It is one thing that it is actually attention-grabbing whenever you get into the affected person aspect of it, particularly when it is a uncommon illness. So we have now one thing right here that I feel we the interplay half is admittedly, actually essential to us. So and it is not simply there but additionally with the higher tier of the onc chemo group. It is also being concerned with them and in discussions with them. and our having our chief medical officer on board helps us an terrible lot there, just because all of them know him. He is he is a rock star in that in that universe. So you’ve got received your advertising emphasis must be on growing your audience, which might be primarily these hematologists and oncologists.
Stewart Gandolf (Healthcare Success): Yeah, for certain. After which truly as an company, we oftentimes will assist corporations goal particular physicians primarily based upon their the scripts they’re writing, the sorts of sufferers they’re seeing. And also you we talked about that additionally offline about which sufferers are literally by means of claims information are you understand the most effective ones for you. So assist our viewers perceive the place are you in that section?
Leonard Mazur (Citius Prescribed drugs): So principally we have managed yeah, we have managed to establish each single treater by utilizing the claims information, which is which is per it’s a must to buy it, and it will inform you the variety of CTCL circumstances being handled by that treater. So we have managed we have now stratified that. We have that damaged out, we all know which you understand which facilities they’re affiliated with. The educational facilities together with the a few of the neighborhood outreach facilities as nicely. That is that is one the place the remedy is one week on, three weeks off. So there’s there may very well be some journey concerned there if want be.
However we have we have additionally arrange a complete program the place we’re doing we have now a affected person hub. We do all the pieces to make it possible for affected person will not be inconvenienced in in the slightest degree and if there is a billing situation, we bounce proper into it to make it possible for they’re that it will get resolved instantly. What’s attention-grabbing right here is that we didn’t have a pricing battle for pricing approval. The reason is is as a result of there have been already two, three different opponents out there. Our pricing was proper in keeping with them, so we did not should go for particular permission or wait months for that to occur. We received it pr fairly rapidly.
Stewart Gandolf (Healthcare Success): Wow, that is nice. How do you convey all this stuff collectively? You already know, we’re speaking about advocacy, we’re speaking about digital advertising, you’ve got received a subject gross sales group, you are additionally working with Eversana. Like how do you convey is there any tips to bringing all these items collectively or to convey it constructing synergy? So it is a sequence of ways.
Leonard Mazur (Citius Prescribed drugs): I you understand what it’s? I am so used to swiftly, you understand, you are not even identified. No one even is aware of you exist, and now swiftly you are within the market. Okay.
I am very accustomed to that. So I’ve finished that a number of instances and I do know what meaning. So, you understand, it’s a must to get state licenses, you have to get approvals for each state, you gotta have make it possible for all the pieces is ready up accurately. So and also you gotta usher in folks that do perceive that and know what meaning to execute and try this. So and on a advertising aspect we had been lucky that we employed anyone from Regeneron who as a director of selling right here with us, Omar Lon Sari, he is actually excellent. He is finished a terrific job for us. So you have got a crew you want a crew effort. It is a crew effort. And also you gotta be sure to’ve received a terrific crew that may work collectively. And that is essential to me and it is essential to all of us. I feel I like transparency so there’s all the pieces is aboveboard with us. All people is aware of what is going on on within the firm on a regular basis, it doesn’t matter what the roles are. All of us have an understanding of what one another is doing.
Stewart Gandolf (Healthcare Success): That is nice. You talked about Eversana, which I am if you happen to’re far more knowledgeable at this than I’m, but it surely does make intuitive sense to work with a accomplice on that. Do you are feeling like that is essential with a drug like yours? With out having the infrastructure behind it?
Leonard Mazur (Citius Prescribed drugs): 100% it helped us tremendously. So it took away a l a stage of concern that you’d have, you understand, ‘trigger you keep up nights worrying about getting all these items in place and ensuring that is all being executed and particularly in terms of pharmaceuticals, that are once more some of the regulated components of something in our marketplaces right here within the within the US or elsewhere on the planet. So with that you just’re coping with professionals at Eversana who know their finish. They know precisely what must be finished and the way it must be finished. In order that w one of many one of many issues I ought to level out for you is that we have no administration trainees, summer season internships, we do not have something like that. All proper. Our firm is completely skilled. All people in our firm has a monitor document of expertise and accomplishment. And that is actually essential.
Stewart Gandolf (Healthcare Success): Yeah, the stakes are excessive. Simply even managing the pipeline of the medicine and you understand all of the completely different laws and all of the various things that occur.
Leonard Mazur (Citius Prescribed drugs): Proper. Proper.
Stewart Gandolf (Healthcare Success): There’s a lot there for certain. the let’s speak about neighborhood oncology. The as an company we labored with a whole lot of huge teams for neighborhood oncology and you have the tutorial medical facilities, which oftentimes is the area for uncommon illnesses, however neighborhood oncology is one other factor. Are you guys working with neighborhood oncologists? Is that built-in into your plan?
Leonard Mazur (Citius Prescribed drugs): Yeah, in order that’s a part of our advertising plan as nicely is that we are also organising facilities outdoors away from the from the tutorial facilities the place we all know these sufferers can be capable of entry the remedy. That is an infusion remedy. So there are facilities which might be positioned at a long way from the massive educational facilities that may deal with these sufferers. So sure, that’s a part of our entire advertising program proper now as we’re as we’re executing it.
Stewart Gandolf (Healthcare Success): And so one other query, a whole lot of medicine, nearly all of them in all probability, have key opinion leaders being a key a part of the advertising program. You talked about that your chief medical officer is already a fairly acknowledged rock star.
is that’s he your main KOL? Do you have got different key opinion leaders?
Leonard Mazur (Citius Prescribed drugs): No, no, no, no, no, no. We’ve we have now like 20 of them that we work with. They’re a part of our they’re a part of our sci our scientific advisory board. We meet with them on the on the varied conferences the place they’re gonna be. So we have that base lined very well. After which on prime of that, we have now two of our reps try this’s their goal, are the important thing opinion leaders. They usually develop relationships with them as nicely. So we have that we have got that lined. I ought to add that the best way we have now that gross sales pressure structured is a part of it additionally consists of medical science liaison. So these are professionals who can are available in and communicate to a doctor about off label makes use of of a drug underneath FDA pointers.
Stewart Gandolf (Healthcare Success): Okay, that makes whole sense. So that you talked about, you understand, different indications that this drug is perhaps helpful for. I imply, you are already making an attempt to only juggle a complete launch. How do you handle that? Like ‘trigger you possibly can have the distraction issue like, “wait a minute, we have now this downside over right here to resolve.”
Leonard Mazur (Citius Prescribed drugs): No, I you understand what, so hear I am contacted no less than as soon as per week about some alternative someplace. Proper. So I filter these out. often I’ve some standards that should be met earlier than we might entertain something.
Stewart Gandolf (Healthcare Success): All proper. Properly then, you understand, as we’re wrapping up right here, you’ve got spent a long time within the business. You are in the course of an thrilling launch. Like what, you understand, can the you understand, our viewers consists of executives and communicators and CEOs or suppliers and in addition biotech, however what can they study from, you understand, the expertise that you’ve with this firm and particularly when it comes to taking a promising remedy or concept into an precise enterprise?
Leonard Mazur (Citius Prescribed drugs): Properly, you understand what, I feel it is like this. I feel hopefully what they’d study is you could’t do that in isolation, and relationships, whether or not they’re inner or exterior, are essential to the success of your of your organization. So whether or not that features fundraising, whether or not that features relationships with key opinion leaders, however relationships are and internally you wanna just remember to’re you’ve got received an actual nice crew of individuals which might be working collectively and dealing in concord they usually all know what our targets are. We at all times meet with our individuals and go and canopy all the pieces. So but it surely’s the connection aspect, greater than anything, inner and exterior.
Stewart Gandolf (Healthcare Success): You already know, it is humorous too, as a result of in our tradition as we speak, there’s a lot quick gratification. And I can see the complexity of beginning doing what you had been doing right here, simply though it is find yourself, it is a know who to ask is like would save years of developmental time, proper? If you did not have the relationships, the place would you even begin? And so you possibly can spend eternally. And there is a e-book I keep in mind studying again within the 80s or 90s by Harvey McKay, which was Dig Your Properly Earlier than You are Thirsty. And the entire level of that e-book was construct your relationships earlier than you want them. And that is a long run view, but it surely’s so highly effective.
So I would love at hand another feedback on that or recommendation to folks that you understand what at any stage, I’ve CEOs and I’ve junior individuals, like, however at any stage, inform me about simply a few of that.
Leonard Mazur (Citius Prescribed drugs): So true. So a because it turned out later in my profession in the end I reconnected with that CEO of Cooper Labs and he turned out to be a terrific sounding board for me. He was a really exhausting nosed particular person, however he had actual sensible recommendation and I’d name him periodically and discuss to him about various things. various things the place I wanted some enter.
Stewart Gandolf (Healthcare Success): That is wonderful. So I feel that I’d simply say for as an other than my very own life now as CEO of the corporate, you understand, again in my earlier days, my youthful days, it’s totally scrappy simply getting one thing going. However as we speak, I gotta inform you, being once I go to a commerce present and I do know dozens of individuals, it’s totally satisfying and to know the variety of individuals. And I did not actually take that very set very It wasn’t deliberate, it developed over time, however as I received higher at it and as I developed extra relationships, I can see the worth of it in a means that wanting again and the youthful me, geez, I want it could have spent a little bit extra effort on that, as a result of it is actually lots simpler.
Properly, Leonard, I inform you what, this was enjoyable. It is a subject that I believed could be actually an attention-grabbing one for our viewers. And hopefully if you happen to’re listening, you comply with take an entrepreneurial journey into the world of pharmaceutical drug growth and There’s lots there to get a drug taking place from scratch. So I admire your time as we speak.
Leonard Mazur (Citius Prescribed drugs): Yep. So thanks for giving me the platform to speak that to your viewers.
Stewart Gandolf (Healthcare Success): Nice. Thanks, Leonard.
Stewart Gandolf (Healthcare Success): And you understand, there’s some good locations, however you understand what? Spain’s fairly it is not the one place on the planet that is superb. Spain’s
Leonard Mazur (Citius Prescribed drugs): True. That is
Stewart Gandolf (Healthcare Success): Spain’s fairly good too. In order that was
Leonard Mazur (Citius Prescribed drugs): Yeah, I can think about. So
Stewart Gandolf (Healthcare Success): cling on. I what okay, I am able to go right here. So Leonard, I need to be sure is to pronounce your final identify, is it Mazer? How do I pronounce your final identify? Okay.
Leonard Mazur (Citius Prescribed drugs): That is that is Mazer, appropriate.
Stewart Gandolf (Healthcare Success): And Let’s examine, chairman, CEO and chairman of is it Sidious Oncology?
Leonard Mazur (Citius Prescribed drugs): Each. So Sidious Prescribed drugs is the father or mother firm and Sidious Oncology is a sub that is now mark began advertising a an accepted most cancers drug.
Stewart Gandolf (Healthcare Success): And that is lymphier.
Leonard Mazur (Citius Prescribed drugs): Right.
Stewart Gandolf (Healthcare Success): Okay, nice. All proper, nice. So we’re recording now. I am simply gonna get began. Do you have got any questions earlier than we get going?
Leonard Mazur (Citius Prescribed drugs): Nope.
Stewart Gandolf (Healthcare Success): Okay. so let me simply undergo my notes right here once more. It has been some time.
Leonard Mazur (Citius Prescribed drugs): I can perceive.
Stewart Gandolf (Healthcare Success): Did it did I ship you over the questions prematurely?
Leonard Mazur (Citius Prescribed drugs): Someplace I’ve received them, yeah. I haven’t got them proper in entrance of me, however I’d hope so. I have been at it for some time.
Stewart Gandolf (Healthcare Success): Okay. That is humorous. you may be I you understand your stuff nicely. I am certain you may be disillusioned. Yeah. And it you mentioned it was Mazer, appropriate? I simply need be sure I get that proper. Leonard Maser. All
Leonard Mazur (Citius Prescribed drugs): Proper, proper.
Stewart Gandolf (Healthcare Success): proper. Whats up and welcome to the Healthcare Success Podcast. Right this moment I am interviewing Leonard Maser, who’s CEO and Chairman of Sidious Prescribed drugs. To begin with, welcome, Leonard. Thanks.
Leonard Mazur (Citius Prescribed drugs): So thanks. It is a pleasure to be right here and I look and I thanks for the chance to have the ability to take part on this podcast. Thanks once more.
Stewart Gandolf (Healthcare Success): Nice. I am yeah, I am wanting ahead to moving into it. And there is a lot. whenever you your crew reached out to us, there’s a whole lot of issues right here I believed could be related for my viewers and a few new issues to speak about and a few thrilling, enjoyable issues to speak about as nicely within the pharmaceutical world. So, initially, one of many questions that I needed to start out with is give our viewers a little bit little bit of context. You spent over 50 years in prescribed drugs, and now you’ve got invested, personally invested Over twenty million {dollars} insidious. Earlier than we get into the drug launch itself, you understand, it is like I’ve we’re gonna speak about all that in a minute, however such as you we talked about this offline, lengthy story, however I wanna hear it. Like, how did you find yourself with twenty two million {dollars} to take a position into your personal biotech firm?
Leonard Mazur (Citius Prescribed drugs): What how did I what?
Stewart Gandolf (Healthcare Success): How did you provide you with the cash to spend money on your personal biotech firm? It sounds such as you’ve had a fairly attention-grabbing profession. So I would love a I would love a background.
Leonard Mazur (Citius Prescribed drugs): Properly, what it’s, it is pr previous to that, I had I used to be a part of my p I had a accomplice and we might purchase and promote pharmaceuticals, branded ones, often off patent. Then we might repurpose them after which we would dump once more. we did that a number of instances they usually had been considered one of them was extraordinarily profitable. We had a serious league. We had a grand slam, not even a house run, in order that’s That is what that is what enabled me to do to do that.
Stewart Gandolf (Healthcare Success): that should have been a enjoyable profession. How’d you choose that? how did you choose how did you get inquisitive about that? I am simply curious. We’ll discuss concerning the different stuff in a second. I am simply I at all times love entrepreneurial tales.
Leonard Mazur (Citius Prescribed drugs): Properly, you understand what it was. so I’ve my profession was fairly conventional. moved up the ladder, and I’d been with a number of corporations. They had been all run by entrepreneurs. the very first firm I used to be with in all probability was an organization I actually, actually I actually I beloved it to inform you the reality. It was run by an entrepreneur by the identify of Parker G. Montgomery and referred to as Cooper Labs. It was they made 100 and fifty acquisitions.
Stewart Gandolf (Healthcare Success): Wow.
Leonard Mazur (Citius Prescribed drugs): You possibly can think about what that setting was like. So principally and I at all times had what I name the entrepreneurial itch within me. I needed to scratch that. So
Stewart Gandolf (Healthcare Success): Yeah.
Leonard Mazur (Citius Prescribed drugs): on the ripe outdated age of fifty, I lastly determined to go by myself. And I shaped a dermatological product firm. I imply I had I had I had no cash, I had nothing, okay? So I it is I constructed that firm on a foundation of relationships that I had with others. So
Stewart Gandolf (Healthcare Success): Yeah.
Leonard Mazur (Citius Prescribed drugs): in the end I put that firm collectively and had income, owned a small manufacturing facility and outdoors of Detroit, Michigan, and in the end offered the corporate to Pierre Fab of France, considered one of France’s largest corporations, as you in all probability know on a worldwide foundation. After which I used to be their US CEO for a few years, then determined I did not need to be working for the French anymore. So I went off by myself once more. And that is once I received into the entire thing about shopping for and promoting medicine. I had a accomplice. We had been we had been whole opposites. It was form of attention-grabbing. And that is what actually made it work. So after which sadly he handed away. And so ul in the end I offered all the pieces. What occurred was I received along with Myron Halubia, who had been the president of Roche Laboratories US. I knew Myron for many years, and I mentioned, Let’s get collectively and type an organization. We’ll see what we are able to in license. We managed to in license a drug from MD Anderson referred to as Minaloc, which was an antibiotic lock answer for sterilizing contaminated catheters. After which We funded all the pieces ourselves and we went alongside for a few years after which determined we needed to take the corporate public. So we did a reverse merger with an one other public firm that allowed us to get a Nasdaq itemizing and we’re off to the races and I you understand, I would be remiss if I did not inform you that deal making is in my blood or my DNA. So Someone got here to me and a banker got here to us, a boutique financial institution, and mentioned, Hey, I am representing Dr. Reddy’s they usually’re divesting a few of their belongings ‘trigger they have been on a they have been buying branded belongings for a generic firm. Then sooner or later they awakened and mentioned, You already know what? We’re not a branded firm. We’re strictly a generic firm. And in order that was a chance for us. This drug lymph concern, that they had a license on it with E Facet Prescribed drugs. They usually had one affected person left on a scientific trial for cutaneous T cell lymphoma. By coincidence, fully by coincidence. A yr earlier than we even did that transaction, we employed a chief medical officer who was a world-renowned knowledgeable in lymphomas. He spent twenty-three years at Roswell Park in Buffalo because the an oncologist accountable for lymphoma and myeloma. He revealed 100 and eighty papers, if you happen to can think about that. And
Stewart Gandolf (Healthcare Success): Wow.
Leonard Mazur (Citius Prescribed drugs): we introduced him on board. That drug, he knew that drug chilly, all proper, knew all the pieces concerning the class. It was it was a terrific match. It labored out. We put forty million {dollars} down on the desk at that time and received acquired that drug. After which that they had one affected person left, that was in September of twenty one by August of twenty 4. We had been we received an approval. So we have been th that is just about how issues began rolling alongside for us.
Stewart Gandolf (Healthcare Success): I adore it. I simply gotta inform you, I like that entrepreneurial spirit. It is this the form of factor that
Leonard Mazur (Citius Prescribed drugs): Yeah.
Stewart Gandolf (Healthcare Success): so we’ll simply have it and it is it is scary and thrilling and invigorating and chances are you’ll wanna do it, however it’s a must to be good at it too. That is the factor.
Leonard Mazur (Citius Prescribed drugs): Properly, you understand what? I occur to stay by sure mottos, okay? One is failure will not be an possibility. See that I received that from I spent I used to be in a Marine Corps reserve, so I received that in Paris Island at one level. So and the opposite one is if you happen to’re not residing on the sting, you then’re taking over an excessive amount of area. So okay.
Stewart Gandolf (Healthcare Success): I adore it. I adore it. We received some classes in entrepreneurship right here too. And like on a smaller scale, proudly owning my very own company, beginning it with a accomplice in the beginning from scratch has at all times been, I simply knew I used to be gonna try this. However you are doing it on a lot larger scale. However it’s been enjoyable trip. And I feel it is both you both get it or you do not. And I at all times took threat. And to this present day I nonetheless take threat. You simply kinda I do not know. It is simply I get used to it. However making an attempt to make them sensible threat, Leonard, not silly threat, sensible threat.
Leonard Mazur (Citius Prescribed drugs): Right. Properly, you understand, once more, what again in my days at Cooper Labs, I realized all about threat taking from the best way the corporate ran and what they did. And I imply, I need you to consider this. This firm principally I helped create Cooper Imaginative and prescient, which we took from ten million to 6 hundred, seven hundred million, turned considered one of one of many world’s largest darkish care corporations. What the what that firm did although, what was actually outstanding, they decided strategically To construct companies round medical specialties. In order that they shaped a dental unit. And that dental unit went out and purchased a tiny little toothbrush firm doing lower than one million {dollars} in income referred to as RLB. Grew to become the
Stewart Gandolf (Healthcare Success): Wow.
Leonard Mazur (Citius Prescribed drugs): world’s largest promoting toothbrush. I did not have something to do with that. I gotta be sure everyone understands that. So however I watched that occur. After which what I noticed was that and it was a terrific instance of the form of threat taking the corporate did. After they had been within the ophthalmic enterprise, that they had a chance for a it was an prolonged put on contact lens referred to as permalens, the primary one. They usually needed to decide about whether or not or to not do scientific trials after which apply with the F for the FDA for an approval. Each guide that got here into the corporate suggested towards it, mentioned the FDA would by no means approve an prolonged put on lens. However there was one PhD that the that the CEO had as his advisor and that one recommended him and mentioned to him, Go for it. It’s going to clear. And he was proper. And the CEO was not a technical man in any respect. He was a lawyer by coaching, finance, you understand, that was his space. However it was form of attention-grabbing that he took that threat, a technical threat, that in all probability individuals would you understand, you’re you out of your thoughts or what? You already know?
Stewart Gandolf (Healthcare Success): It is humorous. That is such a that is a terrific story. It is humorous. I keep in mind I hope I am quoting this proper. This has been a very long time in the past, however I heard a narrative speaking about Warren Buffett taking threat. And Warren Fashion is a worth man. He would know when he purchased an organization that simply had sell-offable belongings that you possibly can no less than just about break even. However what this what you guys are speaking about is
Leonard Mazur (Citius Prescribed drugs): Proper.
Stewart Gandolf (Healthcare Success): a complete completely different world. So let’s that was nice. I am actually glad we most individuals in all probability do not ask you about that stuff, however I simply should know that. And I need to know like how you bought right here. So, you understand what the aim of the interview that began although is you are transferring from the elevating capital to creating capital section. And so what occurs when in a website of an organization now that you are going previous all of the work, you’ve got received approvals, issues are starting to occur. Inform me concerning the adjustments which might be happening.
Leonard Mazur (Citius Prescribed drugs): Yeah. So i it’s a change as a result of as you mentioned, you are going from elevating capital to creating capital. Yeah, not that you will cease elevating capital, however you may will not do it on the similar depth, and depth that you just did earlier than. So however so you’ve got gotta have an organization now, so we had been we had largely technical individuals in an organization for the longest time. So that you had a regulatory, you had anyone with nice experience in CMC, you understand, medical scientific and medical, so all that was a part of the corporate. That was within the firm’s DNA. After which now swiftly now comes a chance to create income. You gotta usher in a advertising group, you gotta usher in anyone that is received a whole lot of experience in directing and launching, which is admittedly, actually essential. That experience particularly. So we had been lucky that we picked up anyone, his identify is Mike McGuire. He spent twenty 5 years at Hop and La Roche accountable for in the end advertising, launched all their main antibiotics, knew the hospital market chilly, and he was a terrific add on to addition to our employees as a result of it received us transferring in that course. So we labored extensively additionally with Eversana. which is a supplier of every kind of providers, largely to smaller biotech pharma corporations. And I had I’ve had a whole lot of expertise prior to now with startups and getting go getting going. And I do know one factor, I do not desire a warehouse ever reporting to me. So that you rent a 3 PL and principally that they handle delivery, billing, invoicing, all that was in place. Reimbursement received in place. We received So you’ve got received all these targets that you have to meet and have the corporate actually poised to start out producing the income. And with that working once more with Everassana, we use them to rent the salespeople that we introduced on board and you’re taking off. So we’re we’re on the level now the place we had for example twenty 5 twenty 4 individuals in an organization. We simply added twenty 9 s within the gross sales pressure, so we have doubled our dimension. And it is it is it is it is completely different. The setting turns into completely different as a result of now you are focusing in on income. And now you are wanting, you understand, and I’ve I’ve by the best way, I have been at all times increasingly co extra comfy with income than anything. So the expertise I had right here, I went by means of all these years all these years of no income and simply elevating capital. And I gotta say I It was it was such a wierd expertise for me as a result of I used to be so accustomed to having income on a regular basis. And ‘trigger income can cowl in our business, income can cowl a whole lot of sins in case you have excessive gross revenue margins. So you understand, so with that I d it was it w it was it was totally completely different. It was simply a wholly completely different environment, tradition, all the pieces about it was fully completely different. So
Stewart Gandolf (Healthcare Success): I consider it. It is it is enjoyable. I had
Leonard Mazur (Citius Prescribed drugs): I you understand, I needed to get used to it, so
Stewart Gandolf (Healthcare Success): a good friend of mine who used to personal a drywall firm, had a bunch of individuals working for him. When he lastly retired, he mentioned, It is simply so bizarre to not have individuals on the market getting cash for me. It is it is like,
Leonard Mazur (Citius Prescribed drugs): Proper.
Stewart Gandolf (Healthcare Success): wow, it should have been a enjoyable firm, however was that straightforward it sounds too straightforward. So I need to take a step again. You talked about Lymphear a second in the past and about and the way you understand, you the story a little bit bit about like how you’ve got found it. It was, I feel, accepted again in 2024, commercially launched in 25 on the finish, very finish of 2025. individuals outdoors the business might not might assume as soon as you bought FDA approval, it is the end line. However after all, as you are alluding to, you understand, that is only the start. So, what truly has to occur? I imply, you’ve got already talked about a few of the belongings you’ve finished, however what different issues should occur to get an improved remedy in place? Like, what are a few of the essential
Leonard Mazur (Citius Prescribed drugs): So it is like this. We truly didn’t launch till twenty sixth as a result of what occurred was that s the capital markets took a nosedive after we get we get accepted. And I did not have suffici I actually did not have enough capital to launch. So we did different issues to prep, get all the pieces prepared, however I needed to wait till these markets actually began to recuperate. After which I received we managed to boost the capital. So We launched in twenty-six and we did it in two levels. so all twenty 9 individuals are on board as of this simply this previous September. So it was nearly two years from the time it received accepted earlier than we truly received to {the marketplace}. We launched we truly shipped the drug to wholesalers and all the pieces again to start with of twenty-six and received the pipeline all prepared in order that the as soon as the Salesforce was absolutely in place. they’d be capable of go in there they usually did not have to fret about something besides promote the drug to the oncologist or the hematologist. So we had a we had a it is form of a special expertise due to that. So however we’re there and we have I feel we have now a terrific drug. It is received a terrific future forward of it. It is for a really uncommon most cancers referred to as cutaneous T lymphoma. It solely has the which solely has three thousand sufferers within the within the US. So it is a a lot smaller market section, a lot smaller audience. And the specialty aspect is one thing I am very accustomed to. I’ve at all times been interested in smaller specialties the place you do not want a military. You possibly can go in and you’ll construct a enterprise with a smaller variety of individuals. You do not it is not like main care the place you gotta have a thousand individuals no less than on the market within the market. I or I am I am not a believer in that. So I attempt to avoid these sorts of conditions if in any respect attainable.
Stewart Gandolf (Healthcare Success): So did we talked offline, it has been some time. Was Lympheer was this initially the concentrating on or was this a type of joyful circumstances the place Lymphia was developed for one thing else after which it turned out this was the precise most cancers for it to
Leonard Mazur (Citius Prescribed drugs): So what occurred was Linphir had its personal historical past. It had been in the marketplace, E SI had it in the marketplace after which they principally that they had a producing requirement. they needed to modify the drug. They did not should take it off the market. The issue was it was a tough drug to make. They’d inadequate stock to do what the FDA had requested them to do, in order that they determined to tug it off the market whereas they accomplished the extra assessments that the FDA needed or and changes. After which once they went again into the FDA with all the pieces, the FDA mentioned to them, Sorry, however now you have got you have got a brand new drug. You gotta run one other scientific trial. So okay.
Stewart Gandolf (Healthcare Success): Yeah.
Leonard Mazur (Citius Prescribed drugs): So and so ESI continued with that they usually’ve in a course of they outlicensed it to Dr. Reddy’s however they did all of the work. They did all the pieces. So this drug has gone by means of it is received it is received historical past to it. However the but it surely’s a great drug. It is received good outcomes for it. And it is also received extra legs for the longer term when it comes to potential different makes use of. So a an investigator on the College of Pittsburgh determined to check this drug with an investigator IND To check this drug mixed with Qtruda. And what he did is now we’re indicated in blood cancers. He selected to check this in stable tumors in feminine cancers solely, primarily endometrial and ovarian, very exhausting cancers to deal with. And what and the rationale he did is as a result of lymphere has a really distinctive mechanism of motion. It lowers one thing often called T Rex. within the microenvironment of a most cancers cell. And whereas key truda will increase T regs. And what you actually need to do briefly is it brings these T Rex down considerably. In order that’s why this investigator selected to take a look at that mixture. And what he discovered is it is attention-grabbing, he received constructive information, I am going to offer you an instance, 33% goal response charge in endometrial the place nor usually It may very well be in a single digits. These two cancers are actually powerful. They’re brutal. They’re exhausting to deal with. And I feel there’s there’s some actually stable potential there. we even have one other investigator I and D underway on the College of Minnesota the place it is being checked out mixed with CAR T, which is one other type of breakthrough most cancers remedy. So I feel we received one thing right here that additional scientific information will show it out. So Properly we’re we’re on that. And there is the c the that drug it is form of attention-grabbing that it is kinda it is growing this manner. It is not one thing that we anticipated on the time that once we once we acquired the drug. We thought we had been gonna be strictly doing CTCL and that was the market alternative for us. However now as soon as all that began coming into play, that actually opened up the world for us.
Stewart Gandolf (Healthcare Success): Yeah, it is wonderful upside. It is humorous, you understand, going again to our earlier dialog, speaking about threat, after which, you understand, going by means of and discovering out, whoops, you want one other scientific trial when the previous firm owned the drug. Like that is not a great threat. After which swiftly, wait, we have now upside right here, large upside. Like that is insane.
Leonard Mazur (Citius Prescribed drugs): Yeah.
Stewart Gandolf (Healthcare Success): and it is humorous too, as a result of on this case, that is an space that on the pharma aspect, I am not as near, and I can see how Entrepreneurs such as you might be the glue that brings some a drug like this to life, proper? It is not everyone that does this particular form of drug and it is simply it sounds prefer it discovered s sq. into your candy spot. the you understand, uncommon illness medicine. We have had some visitors on our podcast earlier than speaking about uncommon illness and the way that goes whenever you solely have a number of thousand sufferers as a audience to assist, however Past the truth that you want lots much less salespeople, what different issues are distinctive to the uncommon illness market as you guys eager about increasing? for instance, are you focusing all of your energies on educational medical facilities? Are you concerned with shopper advocacy teams? Like what are a few of the issues which might be actually essential to you?
Leonard Mazur (Citius Prescribed drugs): Sure, in order that it is attention-grabbing that you just talked about that, the patron advocacy teams as a result of on this specific most cancers, there’s a shopper group of okay sufferers which have CTCL. They’re lively, they’ve their very own their very own publication, they maintain annual conferences. And we have we have reached out and we’re we’re in we’re involved with them, working together with them, offering them with the inf data on our drug. So it is It is one thing that it is it is actually attention-grabbing whenever you get into the affected person aspect of it, particularly when it is a uncommon illness. So we have now we have now one thing right here that I feel we the interplay half is admittedly, actually essential to us. So and it is not simply there but additionally with the higher tier of the onch chemo group. It is also being concerned with them and in discussions with them. and our having our chief medical officer on board helps us an terrible lot there, just because all of them know him. He is he is a rock star in that in that universe. So it is you’ve got received your advertising emphasis must be on growing your audience, which might be Primarily these hematologists and oncologists.
Stewart Gandolf (Healthcare Success): Yeah, for certain. After which truly as an company, we oftentimes will assist corporations goal particular positions primarily based upon their the scripts they’re writing, the sorts of sufferers they’re seeing. And also you we talked about that additionally offline about which sufferers are literally by means of claims information are you understand the most effective ones for you. So assist our viewers perceive what the place are you in that section? That is a fairly widespread however very misstratue.
Leonard Mazur (Citius Prescribed drugs): So principally we have managed yeah, we have managed to establish each single treater by utilizing the claims information, which is which is per it’s a must to buy it, and it will inform you the variety of CTCL circumstances being handled by that treater. So we have managed we have now stratified that. We have that damaged out, we have we all know which you understand which facilities they’re affiliated with. the tutorial facilities together with the a few of the neighborhood outreach facilities as nicely. That is that is one the place the remedy is one week on, 5 three weeks off. So there’s there may very well be some journey concerned there if want be. However we have we have additionally arrange a complete program the place we’re doing we have now a affected person hub. We do all the pieces to make it possible for affected person will not be inconvenienced in in the slightest degree And if there is a billing situation, we bounce proper into it to make it possible for they’re that it will get resolved instantly. We the what’s attention-grabbing right here is that we didn’t have a pricing battle for pricing approval. The reason is is as a result of there have been already two, three different opponents out there. Our pricing was proper in keeping with them, so we did not should we did not should go for particular permission or wait months for that to occur. we received it pr fairly rapidly.
Stewart Gandolf (Healthcare Success): Wow, that is nice. How do you convey all this stuff collectively? You already know, we’re speaking about advocacy, we’re speaking about digital advertising, you’ve got received a subject gross sales group, you are additionally working with Eversana. Like how do you convey is there any tips to bringing all these items collectively or to convey it constructing synergy? So it is a sequence of ways.
Leonard Mazur (Citius Prescribed drugs): I you understand what it’s? I am so used to swiftly, you understand, you go you have got you are not even identified. No one even is aware of you exist, and now swiftly you are within the market. Okay.
Stewart Gandolf (Healthcare Success): Yeah.
Leonard Mazur (Citius Prescribed drugs): I am very accustomed to that. So I’ve finished that a number of instances and I do know what meaning. So, you understand, it’s a must to get state licenses, you have to get approvals for each state, you gotta have make it possible for all the pieces is ready up accurately. So and also you gotta usher in folks that do perceive that and know what meaning to execute and try this. So and on a advertising aspect we had been lucky that we employed anyone from Regeneron who as a director of selling right here with us, Omar Lon Sari, he is actually excellent. He is finished a terrific job for us. So that you gotta you gotta convey you gotta have a crew you want a crew effort. It is a crew effort. And also you gotta be sure to’ve received a terrific crew that may work collectively. And that is essential to me and it is essential to all of us. I feel I like transparency so there’s all the pieces is above board with us. All people is aware of what is going on on within the firm on a regular basis, it doesn’t matter what the roles are. All of us have an understanding of what one another is doing.
Stewart Gandolf (Healthcare Success): that is nice. Any you talked about Everson, which I am if you happen to’re far more knowledgeable at this than I’m, but it surely does make intuitive sense to work with a accomplice on that. Do you are feeling like that is essential with a drug like yours? with out having the infrastructure behind it?
Leonard Mazur (Citius Prescribed drugs): Oh absolut I it i it helped us tremendously. So it took away a l a stage of concern that you’d have, you understand, ‘trigger you keep up nights worrying about getting all these items in place and ensuring that is all being executed and particularly in terms of pharmaceuticals, that are once more some of the regulated components of something in our marketplaces right here within the within the US or elsewhere on the planet. So with that You are coping with professionals at Aversana who know their finish. They know precisely what must be finished and the way it must be finished. In order that w one of many one of many issues I ought to level out for you is that we have no administration trainees, summer season internships, we do not have something like that. All proper. our firm is completely skilled. All people in our firm has a monitor document of expertise and accomplishment. And that is
Stewart Gandolf (Healthcare Success): Yeah.
Leonard Mazur (Citius Prescribed drugs): actually essential.
Stewart Gandolf (Healthcare Success): Yeah, the stakes are excessive. Simply even managing the pipeline of the medicine and you understand all of the completely different laws and all of the various things that occur.
Leonard Mazur (Citius Prescribed drugs): Proper. Proper.
Stewart Gandolf (Healthcare Success): there’s a lot there for certain. the let’s speak about neighborhood oncology. The as an company we labored with a whole lot of huge teams for neighborhood oncology and you have the tutorial medical facilities, which Oftentimes is the area for uncommon illnesses, however neighborhood oncology is one other factor. Are you guys working with neighborhood oncologists? Is that built-in into your plan?
Leonard Mazur (Citius Prescribed drugs): Yeah, in order that’s a part of our advertising plan as nicely is that we are also organising facilities outdoors away from the from the tutorial facilities the place we all know these sufferers can be capable of entry the remedy. That is an effusion remedy. So there are facilities which might be positioned at a long way from the massive educational facilities that may that may deal with these sufferers. So sure, that’s That’s a part of our entire advertising program proper now as we’re as we’re executing it.
Stewart Gandolf (Healthcare Success): And so one other query, a whole lot of medicine, nearly all of them in all probability, have key opinion leaders being a key a part of the advertising program. You talked about that your chief medical officer is already a fairly acknowledged rock star.
Leonard Mazur (Citius Prescribed drugs): Proper.
Stewart Gandolf (Healthcare Success): is that’s he your main KOL? Do you have got different key opinion leaders?
Leonard Mazur (Citius Prescribed drugs): No, no, no, no, no, no. We’ve we have now like twenty of them that we work with.
Stewart Gandolf (Healthcare Success): Okay.
Leonard Mazur (Citius Prescribed drugs): They’re a part of our they’re a part of our sci our scientific advisory board. We meet with them on the on the varied conferences the place they’re gonna be. So we have we have that base c lined very well. After which on prime of that, we have now two of our reps try this’s their goal, are the important thing opinion leaders. So They usually develop relationships with them as nicely. So we have that we have got that lined. I ought to add that the best way we have now that Salesforce structured is a part of it additionally consists of medical science liaison. So these are professionals who can are available in and communicate to a doctor about off label makes use of of a drug underneath FDA pointers.
Stewart Gandolf (Healthcare Success): Okay, that makes whole sense. So that you talked about, you understand, different indications that this drug is perhaps helpful for. I imply, you are already making an attempt to only juggle a complete launch. How do you handle that? Like ‘trigger you possibly can have the distraction issue like, wait a minute, we have now this downside over right here to resolve.
Leonard Mazur (Citius Prescribed drugs): No, I you understand what, so hear I am contacted no less than as soon as per week about some alternative someplace. Proper. So
Stewart Gandolf (Healthcare Success): Yeah, my guess.
Leonard Mazur (Citius Prescribed drugs): so I filter these out. often I’ve some standards that should be met earlier than we might entertain something. So
Stewart Gandolf (Healthcare Success): All proper. Properly then, you understand, as we’re wrapping up right here, you’ve got spent a long time within the business. You’ve got in the course of an thrilling launch. Like what, you understand, can the you understand, our viewers consists of executives and communicators and CEOs or suppliers and in addition biotech, however what can they study from, you understand, the expertise that you’ve with this firm and particularly when it comes to taking a promising remedy or concept into an precise enterprise?
Leonard Mazur (Citius Prescribed drugs): Properly, you understand what, I feel it is like this. I feel hopefully what they’d study is you could’t do that in isolation and relationships, whether or not they’re inner or exterior, are essential to the success of your of your organization. So whether or not that features fundraising, whether or not that features co relationships with key opinion leaders, however relationships are and internally you wanna you wanna just remember to’re you’ve got received an actual nice crew of individuals which might be working collectively and dealing in concord and b all of them know what our targets are. It is it we at all times meet with our individuals and go and canopy all the pieces. So but it surely’s the connection aspect, greater than anything, inner and exterior.
Stewart Gandolf (Healthcare Success): You already know, it is humorous too, as a result of in our tradition as we speak, there’s a lot quick gratification. And I can see the complexity of beginning doing what you had been doing right here, simply though it is find yourself, it is a know who to ask is like would save years of developmental time, proper? If you did not have the relationships, the place would
Leonard Mazur (Citius Prescribed drugs): Proper.
Stewart Gandolf (Healthcare Success): you even begin? And so you possibly can spend eternally. And there is a e-book I keep in mind studying again within the 80s or 90s by Harvey McKay, which was Dig Your Properly Earlier than You are Thirsty. And the entire level of that. e-book was construct your relationships earlier than you want them. And that is a protracted,
Leonard Mazur (Citius Prescribed drugs): Yeah.
Stewart Gandolf (Healthcare Success): long run view, but it surely’s so highly effective.
Leonard Mazur (Citius Prescribed drugs): Oh.
Stewart Gandolf (Healthcare Success): yeah. So I would love at hand another feedback on that or recommendation to folks that you understand what at any
Leonard Mazur (Citius Prescribed drugs): So can I inform that’s
Stewart Gandolf (Healthcare Success): stage, I’ve CEOs and I’ve junior individuals, like, however at any stage, inform me about simply a few of that.
Leonard Mazur (Citius Prescribed drugs): So true. So a because it turned out later in my profession in the end I reconnected with that CEO of Cooper Labs and he turned out to be a terrific sounding board for me. He was very exhausting nosed particular person, however he had actual sensible recommendation and I’d name him periodically and discuss to him about various things. various things the place I wanted some enter.
Stewart Gandolf (Healthcare Success): That is wonderful. So
Leonard Mazur (Citius Prescribed drugs): Yeah.
Stewart Gandolf (Healthcare Success): I feel that I’d simply say for as an other than my very own life now as CEO of the corporate, you understand, again in my earlier days, my youthful days, it’s totally scrappy simply getting one thing going. However as we speak, I gotta inform you, being once I go to a commerce present and I do know dozens of individuals, it’s totally satisfying and to know the variety of individuals. And I did not actually take that very set very It wasn’t deliberate, it developed over time, however as I received higher at it and as I developed extra relationships, I can see the worth of it in a means that wanting again and it the youthful me, geez, I want it could have spent a little bit extra effort on that, as a result of it is actually lots simpler. Properly, Leonard, I inform you what, this was enjoyable. It is a subject that I believed could be actually an attention-grabbing one for our viewers. And hopefully if you happen to’re listening, you comply with take an entrepreneurial journey into the world of pharmaceutical drug growth and There’s lots there to get a drug taking place from scratch. So I admire your time as we speak.
Leonard Mazur (Citius Prescribed drugs): Yep. So thanks thanks for g giving me the platform to speak that to your viewers.
Stewart Gandolf (Healthcare Success): Nice. Thanks, Lennon.
Leonard Mazur (Citius Prescribed drugs): Okay, bye.




